Respiratory syncytial virus (RSV) pneumonia in BMT recipients carries a mortality rate of approximately 50-70% despite ribavirin (Virazole) treatment. In both immunocompetent and immunocompromised animal models, RSV neutralizing antibodies rapidly reduce pulmonary virus load after a single dose. RSV-IGIV (RespiGam) is an IgG immune globulin with high concentrations of RSV neutralizing antibody (Ͼ19 200 MU/ml). From June 1991 to February 1996, a compassionate-use protocol using RSV-IGIV for treatment of RSV infections was conducted. Eleven children at multiple centers, mean age 3.3 years (4 months to 9 years), were undergoing BMT and met the protocol criteria. They received a single 1500 mg/kg dose of RSV-IGIV infused over 12 h at a median of 5 days (1-37 days) after RSV symptom onset. Ten of these patients received prior or concurrent aerosolized ribavirin. Serum RSV neutralizing titers were measured in five patients and showed a 3-to 30-fold increase 24 h after RSV-IGIV infusion. Adverse events were mild. One of 11 (9.1%) patients died from their RSV illness (91% RSV survival). In comparison to previously published reports, RSV-IGIV treatment of RSV pneumonia in BMT patients may increase survival above that in such patients treated with ribavirin alone. Bone Marrow Transplantation (2000) 25, 161-165. Keywords: respiratory syncytial virus; bone marrow transplantation; immune globulin; treatment; ribavirin; palivizumab Respiratory syncytial virus (RSV) is a well recognized and often fatal complication of bone marrow transplantation. Upper or lower respiratory tract infection (URTI/LRTI) with RSV has been reported to occur in 7% to 20% of hospitalized BMT patients, primarily during the 6-month winter season (November to May).
who develop RSV-LRTI approaches 100% for those not treated with antivirals and 50% to 70% for those promptly treated with ribavirin (Virazole). [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] From the literature, it appears that there are no survivors among RSV-LRTI transplant patients who progress to mechanical ventilation before antiviral therapy has been initiated. 2, 12 Although RSV pneumonia occurring more than 100 days post-BMT has been associated with lower mortality rates, 12, 13 the mortality rate of RSV pneumonia does not differ before and after engraftment during the early post-transplant period. 3, 14 Aerosolized ribavirin is the only Federal Drug Administration (FDA) approved drug for treatment of established RSV disease, 15 but its efficacy in BMT patients with RSV pneumonia is considered poor. The beneficial effects of immune globulin therapy on established RSV disease have been clearly demonstrated in experimental animals. In both immunocompetent and immunocompromised animal models of RSV infection, IgG immune globulin preparations have been shown to rapidly reduce the pulmonary virus load after a single large parenteral dose. [16] [17] [18] [19] In the immunocompetent model, this effect is more profound and rapid than that previously observed with ribavirin treatment in the same animal model. 20 Moreover, combination treatment with ribavirin and standard immune globulin (IGIV) produces greater reduction in pulmonary virus than does ribavirin alone. 21 Combination therapy using aerosolized ribavirin and multiple doses of standard IGIV (500 mg/kg every other day × 12 days) for the treatment of RSV pneumonia in an uncontrolled series of severely immunocompromised adult BMT patients has been reported with favorable results (22% mortality rate). 11 Inasmuch as a single dose of RSV-IGIV produces a more rapid and more profound rise in microneutralization titer than do repeated doses of standard IGIV in severely immunocompromised patients with RSV pneumonia, 22 we report our experience with RSV-IGIV in pediatric bone marrow transplantation.
Materials and methods
RSV-IGIV (RespiGam/MedImmune) is a hyperimmune globulin preparation with high concentrations of RSV-neutralizing antibody (Ͼ19 200 MU/ml). It contains approximately five times the RSV neutralizing titers (mean enrichment 5.2-fold; range 2.6-to 10.0-fold) found in standard IGIV preparations. 23 The product is prepared from selected To be eligible for inclusion into this protocol, patients must have had a nasal swab specimen that was positive for RSV antigen by immunofluorescence or ELISA and either a suspected immunodeficiency disease, including HIV/AIDS, or another life-threatening illness requiring treatment of RSV disease. Informed consent and local investigational review board (IRB) approval were obtained prior to receiving RSV-IGIV. Patients were excluded only if they had a previous reaction to an immune globulin product. Patients who met the protocol criteria received 30 ml/kg (1500 mg/kg) of RSV-IGIV, administered intravenously over a 12-h period. Some patients received further doses of RSV-IGIV for prophylactic reasons after the initial treatment dose.
Vital signs (heart rate, respiratory rate, and blood pressure) were obtained at the beginning, during, at the end of the infusion and additionally 1 h after the infusion. Complications and any adverse effects occurring within 4 weeks after infusion were recorded. Whenever possible, serum for determining RSV neutralizing antibody titer was obtained before and 24 h after RSV-IGIV infusion.
Results
There were 14 patients undergoing marrow transplantation who fulfilled the protocol criteria, received drug and had follow-up reporting. Three of these were adults (two of whom have previously been reported 22 ). Thus, 11 pediatric marrow transplant patients fulfilled the protocol criteria and are analyzed here (Table 1) . Their mean age was 3.3 years, range 4 months to 9 years. All transplants were allogeneic and most were treated during the neutropenic phase of the early engraftment period (Table 2) . At the time of enrolment, 10 of these patients had already received a BMT as necessitated by severe combined immunodeficiency (SCID) (four patients), acute lymphocytic leukemia (ALL) (three patients), acute myelogenous leukemia (AML) (one patient), chronic myelogenous leukemia (CML) (one patient), or Hodgkin's disease (one patient). An additional patient with SCID was enrolled 15 days prior to receiving a BMT.
All 11 patients had antigen-confirmed RSV infection, with lower respiratory tract involvement determined radiographically (six patients) or clinically (five patients). The five patients with LRT involvement diagnosed clinically had no radiographs reported. The radiographic diagnosis consisted of the presence of a new pulmonary infiltrate on either plain film or computed tomography of the chest. A clinical diagnosis of lower respiratory tract involvement consisted of the presence of two or more of the following symptoms as reported by the treating physician: respiratory distress, wheezing, fever, and/or hypoxia (decreased O 2 saturation). Of the five patients whose RSV specimen cultures were known to be reported, all five were RSV culture positive. Nine children received aerosolized ribavirin therapy prior to protocol entry, and 10 received aerosolized ribavirin concurrently with RSV-IGIV; additionally, three received intravenous ribavirin and four received corticosteroids.
Six patients had resolution of RSV-LRTI signs/symptoms after one dose of RSV-IGIV, and these patients were discharged within 7 to 24 days (mean 18.1 days; median 19 days) (See Table 2 ). All five of the multidosed patients also had a noticeable clinical response (symptoms and/or CXR) after their first RSV-IGIV dose, but either had a relapse or ongoing secondary problems, as judged by their treating physician, that made them susceptible to further RSV disease. These five infants (patients 009, 012, 020, 037, 038) received later prophylactic doses of RSV-IGIV until there was evidence of RSV elimination and/or return of adequate T cell function (see Table 2 for timing of RSV-IGIV doses). Four of these infants recovered from their RSV pneumonia and the other died.
In the five patients in whom serum RSV neutralizing titers were measured before and 24 h after infusion, there was a 3-to 30-fold increase in such titers (RSV subtypes A and B); all five of these patients survived. Ten of the 11 patients recovered from their RSV illness, for an overall RSV mortality rate of 9.1% (1/11) in this series of patients ( Table  2 ). The child with SCID who received RSV-IGIV pre-BMT (patient 012, see Table 2 ) improved following initial treatment, but died 41 days following BMT with chronic RSV pneumonia.
Adverse events were reported for four patients and were mostly mild to moderate in nature. All but one, an occurrence of moderate tachycardia, were judged by the attending physician to be unrelated to RSV-IGIV (Table 3) .
Discussion
The 9.1% mortality in this series of patients treated with ribavirin plus RSV-IGIV, compared with the 50-70% mortality rate of such patients given ribavirin alone, 3, 4, 6, 7, 9, 12, 13 or the 22% mortality rate of those given ribavirin plus standard IGIV, 11 would suggest that RSV-IGIV may have an added beneficial treatment effect. In the earlier reported series of patients treated with ribavirin plus standard IGIV,
11

Table 2
Baseline treatment and outcome data of enrolled pediatric patients the survivors were all treated before the possible need for mechanical ventilation. Our series is similar to this, however, one patient (No. 077, see Table 2 ) was on a ventilator when RSV-IGIV was initiated and this child subsequently recovered. In addition, this patient did not receive ribavirin.
(In the aforementioned ribavirin plus IGIV study, 11 three other patients who were started on drug therapy р24 h of respiratory failure requiring mechanical ventilation died of RSV pneumonia.) Since none of these studies were wellcontrolled trials, it is not possible to conclude that RSV-IGIV is superior to standard IGIV when added to ribavirin alone. At the very least, RSV-IGIV offers a more efficient and economical method (ie single-dose, assured high-titer RSV potency, rapid peak plasma levels, less fluid volume, etc) than multi-dosing of standard IGIV. The advantage of achieving a rapid peak anti-RSV titer was suggested in our earlier report of two adult BMT patients with RSV pneumonia (non-intubated) who subsequently survived with RSV-IGIV plus ribavirin treatment. 22 These two patients had an 8-fold mean increase in RSV titer within 24 h compared to a 4-fold increase after 4 to 5 days for two patients given standard IGIV in multiple daily infusions.
It remains unproven whether antibody or immune globulin preparations improve clinical outcomes of established RSV infections. An argument can be made that the type of conditioning this series of largely SCID patients received, or differences in their underlying disease, may have caused or contributed to this suggested treatment effect. Moreover, proving a treatment benefit in a complicated condition such as this by comparing one uncontrolled series to another is difficult. Indeed, despite higher RSV loads being linked to disease severity, 24 large well controlled trials studying RSV-IGIV in the treatment of established RSV disease in previously healthy 25 and high risk 26 infants have failed to show a statistically significant treatment effect (a favorable trend was observed in the previously healthy group 25 ). The reason is most likely due to the fact that infection in immuno-competent patients is rapidly cleared, giving little time for the rapid reduction of virus achieved with passive antibody treatment to manifest itself as observable clinical improvement.
On the other hand, it is important not to indiscriminately extrapolate data generated in immunocompetent infants to make conclusions regarding therapy for RSV disease in the severely immunosuppressed, whose viral dynamics are different. Immunocompetent hosts generally recover completely from RSV infection regardless of specific antiviral therapies, while severely immunosuppressed patients frequently develop progressive fatal pneumonia. Indeed, some practice guidelines have suggested that ribavirin has comparatively better efficacy in the immunosuppressed population. 27 A humanized monoclonal antibody to the F protein of RSV (MEDI-493, palivizumab, Synagis) 28 became available after this protocol closed, and has a similar RSV preventative effect as RSV-IGIV for its indicated use. 29 This monoclonal antibody has also been shown to have an antiviral treatment effect in immunocompetent infants: RSV concentrations in palivizumab-treated patients dropped by 1.7 log at 24 h and 2.5 log at 48 h after a single intravenous 15 mg/kg dose, as compared to a 0.6 log (P = 0.004) and a 1.0 log (P = 0.012) drop in the placebo group at the same time points. 30 Palivizumab is approximately 50 to 100 times more active than RSV-IGIV (RespiGam) in the cotton rat model of RSV prevention (ie Ͼ99% reduction (Ͼ2 log) in pulmonary virus titer with 2.5 to 5.0 mg/kg palivizumab, compared with 125 to 250 mg/kg for RSV-IGIV). Indeed, the commercial product Synagis is dosed at a 1:50 ratio to RespiGam, ie 15 mg/kg vs 750 mg/kg, respectively. For the in vitro microneutralization assay, the RSV-IGIV EC 50 of RSV Long strain is 2.58 ± 0.37 g/ml and that of MEDI-493 (palivizumab) is 0.10 ± 0.03 g/ml (a 26-fold difference in potency). 28 Thus, a similar in vitro and in vivo RSV neutralizing potential would theoretically be achieved by 30 mg/kg to 58 mg/kg of palivizumab as is achieved by 1500 mg/kg of RSV-IGIV (the dose used in this compassionate-use protocol). Palivizumab offers an intriguing option inasmuch as it can deliver even higher and more rapid RSV-neutralizing titers than IGIV or RSV-IGIV, without the dose-limiting constraint of excess fluid volume.
The results obtained in this series of patients, combined with data in animal models, strongly suggest that appropriately controlled studies of high-dose passive RSV neutralizing antibody treatment in BMT patients with RSV infection are warranted. In the meantime, clinicians should carefully screen for RSV in patients undergoing BMT and other severely immunocompromised patients, establish infection control policies to prevent community respiratory virus infections, and be prepared to initiate treatment promptly at the time of earliest signs and symptoms. 1, 31 
